KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $358.6 million.

  • Supernus Pharmaceuticals' Total Non-Current Liabilities rose 2428.27% to $358.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $358.6 million, marking a year-over-year increase of 2428.27%. This contributed to the annual value of $285.0 million for FY2024, which is 584.96% down from last year.
  • Supernus Pharmaceuticals' Total Non-Current Liabilities amounted to $358.6 million in Q3 2025, which was up 2428.27% from $310.7 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Total Non-Current Liabilities registered a high of $826.3 million during Q1 2023, and its lowest value of $285.0 million during Q4 2024.
  • For the 5-year period, Supernus Pharmaceuticals' Total Non-Current Liabilities averaged around $522.1 million, with its median value being $358.6 million (2025).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Total Non-Current Liabilities soared by 2471.31% in 2021, and later crashed by 6096.4% in 2024.
  • Supernus Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $792.8 million in 2021, then decreased by 3.97% to $761.3 million in 2022, then plummeted by 60.24% to $302.7 million in 2023, then fell by 5.85% to $285.0 million in 2024, then increased by 25.84% to $358.6 million in 2025.
  • Its Total Non-Current Liabilities was $358.6 million in Q3 2025, compared to $310.7 million in Q2 2025 and $286.6 million in Q1 2025.